Lutetium-177 EBRGD (Molecular Targeting Technologies)

N/A

Report date: 2025/11/20 16:05:04

Base Information

Drug NameLutetium-177 EBRGD (Molecular Targeting Technologies)

Drug Alias NameLutetium-177 EBRGD - Molecular Targeting Technologies177Lu-EBRGDLu-177 EBRGD177Lu-EB-RGD

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionIonising radiation emittersIntegrin alpha-V/beta-3 binders

TargetsIntegrin alpha-V/beta-3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Biomedical Innovation

China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Biomedical Innovation Molecular Targeting Technologies Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A